Cefditoren dosage and administration: Difference between revisions
Gerald Chi (talk | contribs) (Created page with "__NOTOC__ {{Cefditoren}} {{CMG}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = SPECTRACEF (CEFDITOREN PIVOXIL) TABLET, FILM COATED SPECTRACEF ...") |
Gerald Chi (talk | contribs) mNo edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Dosage and Administration== | |||
{| | |||
| [[File:SPECTRACEF05.jpg|800px|thumb]] | |||
|} | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = SPECTRACEF (CEFDITOREN PIVOXIL) TABLET, FILM COATED SPECTRACEF (CEFDITOREN PIVOXIL) TABLET, FILM COATED [CORNERSTONE THERAPEUTICS INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f732ed2f-48b9-4331-87ab-81b5fbe728aa | publisher = | date = | accessdate = }}</ref> | ====Patients with Renal Insufficiency==== | ||
No dose adjustment is necessary for patients with mild renal impairment (CLcr: 50-80 mL/min/1.73 m2). It is recommended that not more than 200 mg BID be administered to patients with moderate renal impairment (CLcr: 30-49 mL/min/1.73 m2) and 200 mg QD be administered to patients with severe renal impairment (CLcr: <30 mL/min/1.73 m2). The appropriate dose in patients with [[end-stage renal disease]] has not been determined. | |||
====Patients with Hepatic Disease==== | |||
No dose adjustments are necessary for patients with mild or moderate hepatic impairment (Child-Pugh Class A or B). The pharmacokinetics of cefditoren have not been studied in patients with severe hepatic impairment (Child-Pugh Class C).<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = SPECTRACEF (CEFDITOREN PIVOXIL) TABLET, FILM COATED SPECTRACEF (CEFDITOREN PIVOXIL) TABLET, FILM COATED [CORNERSTONE THERAPEUTICS INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f732ed2f-48b9-4331-87ab-81b5fbe728aa | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 01:41, 6 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Dosage and Administration
 |
Patients with Renal Insufficiency
No dose adjustment is necessary for patients with mild renal impairment (CLcr: 50-80 mL/min/1.73 m2). It is recommended that not more than 200 mg BID be administered to patients with moderate renal impairment (CLcr: 30-49 mL/min/1.73 m2) and 200 mg QD be administered to patients with severe renal impairment (CLcr: <30 mL/min/1.73 m2). The appropriate dose in patients with end-stage renal disease has not been determined.
Patients with Hepatic Disease
No dose adjustments are necessary for patients with mild or moderate hepatic impairment (Child-Pugh Class A or B). The pharmacokinetics of cefditoren have not been studied in patients with severe hepatic impairment (Child-Pugh Class C).[1]
References
Adapted from the FDA Package Insert.